CERS6 and metabolic dysfunction-associated steatotic liver disease: Additionally, the increase in hepatic saturated C16 ceramide is of particular interest, as prior studies have revealed its involvement in metabolic syndrome and MASLD development through its production by ceramide synthase 6 (38, 39).